Medical cannabis as a business opportunity

TL;DR

• TPA revision 1.8.2022: physicians prescribe directly, no FOPH exception required.
• Pickup at pharmacies; insurers reimburse on indication (case-by-case).
• Market size: ~CHF 15 M (2024), growth ~50 %/year.
• Players: Bedrocan (NL), Tilray, Aurora, Swiss Extract, Hänseler.

Value chain

• Cultivation (GMP-certified) — mostly imported from NL, DE, CA.
• Processing into extracts/tinctures — by Swiss pharmacies/labs.
• Distribution — wholesalers Voigt/Galenica.
• Dispensing — public pharmacies on prescription.
• Physician training — SGCC & CME providers.

After the TPA revision: how the medical value chain actually works in Switzerland

Since 1 August 2022, physicians prescribe medical cannabis without an FOPH exceptional authorisation. For companies the bottleneck moved: it is no longer per-patient authorisation but product quality, the pharmacy channel and reimbursement. The chain runs producer (GACP/GMP) → manufacturer with a Swissmedic establishment licence → pharmacy with a magistral formula or authorised product → patient.

The commercially decisive field is reimbursement. Coverage by mandatory health insurance is not guaranteed and often runs through case-by-case applications under Art. 71a–d HIO. Successful companies therefore invest less in marketing and more in dossiers: standardised cannabinoid content, stability data, supply reliability and study or registry data that can be put in front of an insurer's medical officer. Supplying raw material without that documentation leaves you interchangeable and price-driven.

• Prescription without FOPH exceptional authorisation since 1 Aug 2022 – reimbursement stays case-by-case.
• A Swissmedic establishment licence is mandatory for manufacture, import and wholesale.
• Standardised potency and stability data are the real competitive advantage.
• Engage pharmacies early – they decide on magistral formulation and availability.

Regulatory requirements for Swiss market entry

Anyone wishing to operate commercially with medical cannabis in Switzerland must deal intensively with the regulatory requirements of Swissmedic and the Federal Office of Public Health (BAG). Although the hurdle of exceptional individual licences for patients was eliminated following legal liberalisation in August 2022, the requirements for market players have remained high. Companies strictly require a corresponding establishment licence from Swissmedic for manufacturing, import and wholesale. This licence requires proof that all processes comply with the strict Good Manufacturing Practice (GMP) guidelines in order to guarantee a consistent quality of the preparations.

The import of medical cannabis into Switzerland is also subject to strict controls and requires specific narcotics import licences. Since a large proportion of raw materials and finished preparations are currently still imported, foreign suppliers must be able to provide seamless proof of compliance with Swiss quality standards. Swiss importers bear full responsibility for compliance with national limit values and the seamless documentation of the supply chain. An incomplete or faulty dossier or deviations in active ingredient content quickly lead to delivery delays and significant financial losses in this highly regulated market environment.

• Mandatory establishment licence from Swissmedic for manufacturing, import and wholesale.
• Strict compliance with Good Manufacturing Practice (GMP) guidelines for all products.
• Required import and export licences under narcotics legislation for the movement of goods.
• Seamless documentation of the supply chain and active ingredient stability as a market prerequisite.

Federalism and cantonal enforcement in practice

Although the Narcotics Act (BetmG) and the Therapeutic Products Act (TPA) are anchored at federal level, actual enforcement lies largely with the Swiss cantons. The cantonal therapeutic products authorities and cantonal pharmacists monitor compliance with regulations in local pharmacies and manufacturing facilities. In practice, this leads to a heterogeneous landscape, as the interpretation of guidelines and the frequency of inspections can vary depending on the canton. For companies, this means they must not only align themselves with federal requirements, but also actively seek direct exchange with the respective cantonal authorities.

Cantonal differences are particularly evident in the monitoring of magistral formulations in pharmacies. While some cantons take very liberal approaches to the approval of certain formulations, others require detailed proof of stability for each individual mixture. Collaboration with cantonal medical societies also plays a crucial role in strengthening trust in the medical use of cannabis products. Market participants must therefore incorporate regional specificities into their distribution and training strategies to achieve nationwide success.

• Cantonal therapeutic products authorities and cantonal pharmacists as direct local supervisory bodies.
• Varying inspection frequency and interpretation of guidelines depending on the Swiss canton.
• Need to align distribution activities with regional characteristics.
• Importance of cantonal medical associations for the acceptance of medical preparations.

Galenics and product requirements in the Swiss pharmacy market

The Swiss medical cannabis market differs significantly from the recreational market in terms of its product requirements. The focus is on standardized galenic forms that enable precise and reproducible dosing. The most frequently requested and dispensed products are oily solutions, tinctures, and standardized extracts taken orally. These dosage forms offer the advantage of a longer duration of action and easier handling for patients compared to inhalation. For manufacturers, this means they must invest in modern formulation technologies to offer stable and patient-friendly products.

In addition to liquid extracts, cannabis flowers for inhalation are also gaining in importance, although the requirements for microbiological purity are extremely high here. Since the products are often dispensed to immunocompromised patients, contamination must be strictly ruled out. Every batch must be comprehensively tested for heavy metals, pesticides, and moulds. Companies wishing to establish themselves on the Swiss market must therefore not only guarantee the active ingredient content, but also seamlessly demonstrate the absolute purity and biological safety of their products.

• Focus on standardized oily solutions and extracts for precise dosing.
• Extremely high requirements for the microbiological purity of cannabis flowers.
• Comprehensive batch testing for pesticides, heavy metals, and impurities.
• Development of patient-friendly dosage forms as an important competitive factor.

Risk management and legal liability for companies

Handling medical cannabis entails specific legal and financial risks for Swiss companies, requiring systematic risk management. A central aspect is product liability in the event of quality defects or adverse drug reactions. Since these are highly potent substances, dosing errors or contamination can have serious health consequences for patients. Companies must therefore have comprehensive pharmacovigilance systems in place to quickly record adverse reactions and report them to Swissmedic. The risk of product recalls must also be covered by financial reserves and insurance.

Another legal risk concerns the duty of doctors and pharmacists to inform patients about their unfitness to drive. Since a strict zero-tolerance practice with a limit of 1.5 micrograms of THC per litre of blood applies to Swiss road traffic, the consumption of THC-containing medications generally leads to unfitness to drive. Companies should provide information materials that explain this legal situation objectively and unambiguously. Insufficient information can not only lead to liability issues, but also cause long-term damage to the image of the company and the entire industry.

• Necessity of pharmacovigilance systems for reporting adverse effects to Swissmedic.
• High liability risks in the event of quality defects, contamination, or dosage errors.
• Legal risks in connection with the strict zero-tolerance policy in road traffic (1.5 µg/L).
• Importance of objective education on driving incapacity for physicians, pharmacists, and patients.

FAQ